Evidence map›Paper›PMID 31117967›Full record

ArticleBMC cancer2019

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma.

Kailin Wang, Jun Dong, Shasha He, Xia Wang, Chang Jiang, Pili Hu, Jiangui Guo, Xiuyu Cai, Xicheng Wang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kailin WangDepartment of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Guangzhou, 510062, China.
Jun DongDepartment of Integrated Therapy in Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 East Dongfeng Road, Guangzhou, 510060, China.
Shasha HeDepartment of Radiation, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, 510060, China.
Xia WangDepartment of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Guangzhou, 510062, China.
Chang JiangDepartment of Integrated Therapy in Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 East Dongfeng Road, Guangzhou, 510060, China.
Pili HuDepartment of Integrated Therapy in Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 East Dongfeng Road, Guangzhou, 510060, China.
Jiangui GuoDepartment of Radiation Oncology, The First People's Hospital of Foshan, Foshan, 528000, China.
Xiuyu CaiDepartment of Integrated Therapy in Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, 651 East Dongfeng Road, Guangzhou, 510060, China. caixy_84@outlook.com.
Xicheng WangDepartment of Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, 19 Nonglinxia Road, Guangzhou, 510062, China. kailin0352@126.com.ORCID http://orcid.org/0000-0002-3901-4210

Funding

Guangdong Medical Research Foundation A2016011Natural Science Foundation of Guangdong Province 2017A030313764
6 · The paper itself

Abstract

backgroundWe compared the survival outcomes and acute toxicities of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients.

methodsPatients were treated with CCRT alone. CCRT was initiated on the first day of RT. Cisplatin 30-40 mg/m

resultsNinety-three (28.9%) patients received three to 7 cycles of cisplatin weekly (Weekly Group) and 229 (71.1%) patients received two to 3 cycles of cisplatin triweekly (Triweekly Group). Five-year OS (weekly vs. triweekly, 96.7% vs. 88.3%, P = 0.036) and DFS (weekly vs. triweekly, 90.7% vs. 80.5%, P = 0.028) were better in the Weekly Group than in the Triweekly Group. The weekly vs. triweekly 5-year DMFS and LRFS rates were: DMFS, 96.7% vs. 91.4%, χ

conclusionsCompared with Triweekly cisplatin regimen, Weekly regimen may be a better choice during CCRT.

Indexed as

AdultAntineoplastic AgentsChemoradiotherapyCisplatinDrug Administration ScheduleFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNasopharyngeal CarcinomaNasopharyngeal NeoplasmsRetrospective StudiesTreatment OutcomeAntineoplastic AgentsCisplatinCisplatinConcurrent chemoradiotherapyNasopharyngeal carcinomaSurvival

Identifiers

PMID31117967
PMCPMC6532163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.